SCHEMBL21729904

SCHEMBL21729904

O=C(Nc1ccccc1F)Oc1ccc2ccccc2c1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.75
NPC1 O15118 6/20 0.75
NPSR1 Q6W5P4 1/20 0.75
KDM4E B2RXH2 3/20 0.69
POLB P06746 4/20 0.59
TDP1 Q9NUW8 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.50
TRPV1 Q8NER1 1/20 0.50
FAAH O00519 1/20 0.49
EPHX1 P07099 1/20 0.49
KMT2A Q03164 7/20 0.48
MEN1 O00255 5/20 0.48
MAPT P10636 2/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP1A2 P05177 1/20 0.48
HPGD P15428 1/20 0.48
ESR1 P03372 1/20 0.48
ESR2 Q92731 1/20 0.48
PKM P14618 1/20 0.47
NFKB1 P19838 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29484708 1.00 RAB9A (0.75) RAB9ANPC1NPSR1KDM4EPOLB
SCHEMBL10356846 0.82 RAB9A (0.81) RAB9ANPC1NPSR1KDM4ESMN1; SMN2
SCHEMBL14470402 0.79 KDM4E (0.57) KDM4EPOLBTDP1SMN1; SMN2FAAH
SCHEMBL10966689 0.78 KDM4E (0.63) RAB9ANPC1KDM4EPOLBTDP1
SCHEMBL10973980 0.77 POLB (0.81) RAB9ANPC1KDM4EPOLBTDP1
SCHEMBL5577084 0.77 KDM4E (0.62) RAB9ANPC1NPSR1KDM4EPOLB
SCHEMBL9149565 0.76 KDM4E (0.61) RAB9ANPC1NPSR1KDM4ETDP1
SCHEMBL11692269 0.75 KDM4E (0.59) RAB9ANPC1NPSR1KDM4ETDP1
SCHEMBL1837122 0.74 KDM4E (0.59) RAB9ANPC1KDM4EPOLBSMN1; SMN2
SCHEMBL1690756 0.74 ALDH1A1 (0.65) RAB9ANPC1KDM4ETDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220062281-A1 INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION NAT CENTRE FOR BIOLOGICAL SCIENCES TIFR (IN) 2022-03-03 US disclosed
WO-2020035880-A1 INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION NATIONAL CENTRE FOR BIOLOGICAL SCIENCES-TIFR (IN) 2020-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220062281-A1 INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION CD4, CD14, CD69 RAB9A 997/4885NPC1 77/4885NPSR1 813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.